1. Introduction {#sec1-ijms-18-00956}
===============

Membrane-enclosed extracellular vesicles (EVs) include apoptotic bodies, microvesicles and exosomes which are released by various cell types, and have been found in cell culture media, as well as body fluids such as breast milk, urine, amniotic fluids, saliva and blood \[[@B1-ijms-18-00956],[@B2-ijms-18-00956],[@B3-ijms-18-00956],[@B4-ijms-18-00956],[@B5-ijms-18-00956],[@B6-ijms-18-00956],[@B7-ijms-18-00956],[@B8-ijms-18-00956],[@B9-ijms-18-00956],[@B10-ijms-18-00956],[@B11-ijms-18-00956]\]. During EV biogenesis, a number of biological molecules are encapsulated into the EV, including DNA, small RNAs, proteins and lipids which are derived from parental cells \[[@B6-ijms-18-00956],[@B11-ijms-18-00956]\]. However, the real significance of EVs lies in their ability to deliver their contents to recipient cells, thereby altering biological and cellular processes. Furthermore, aberrant delivery of EV cargo to recipient cells has been implicated in several pathologies such as some autoimmune disorders and cancers \[[@B12-ijms-18-00956],[@B13-ijms-18-00956],[@B14-ijms-18-00956],[@B15-ijms-18-00956]\].

Wound healing is a complicated process which involves an overlapping cascade of events characterised into four distinct phases ([Figure 1](#ijms-18-00956-f001){ref-type="fig"}). These include: Haemostasis, where blood loss ceases;The inflammatory phase, characterised by infiltration of immune cells to combat infection and remove cellular debris;The proliferative phase, where fibroblasts and keratinocytes at the wound margins migrate into the wound and increase in cell number to re-establish the barrier function of the skin; andThe remodelling phase, during which reorganisation of the dermis occurs and the preliminary extracellular matrix (ECM), laid down during the earlier phases of the healing response, is remodelled to strengthen the wound area through the reduction of scar tissue \[[@B16-ijms-18-00956]\].

Preliminary studies have shown that EVs may be involved in wound healing through the control of a number of cellular processes \[[@B17-ijms-18-00956],[@B18-ijms-18-00956],[@B19-ijms-18-00956],[@B20-ijms-18-00956],[@B21-ijms-18-00956]\]. Therefore, this review will summarise the role of EVs derived from predominant cells involved in the wound healing process. An overview of EV classification, biogenesis, components, and cell-to-cell communication via EVs is also described.

2. Extracellular Membrane Vesicles (EVs) {#sec2-ijms-18-00956}
========================================

EVs have a phospholipid bilayer similar to the cell membrane, with diameters ranging from 40 nm to 5 µm. In general, EVs can be classified into three subtypes: apoptotic bodies (also known as apoptotic vesicles); microvesicles (also known as shedding vesicles); and exosomes.

2.1. Apoptotic Bodies {#sec2dot1-ijms-18-00956}
---------------------

Apoptotic bodies are the largest vesicle population, with a diameter ranging from 1 to 5 µm and have a heterogeneous morphology. Apoptotic bodies are released when cells undergo apoptosis and therefore they contain various components from their parental cells often including organelles and DNA fragments \[[@B23-ijms-18-00956]\].

Apoptosis and necrosis are major mechanisms of cell death, which produce cell debris but are activated by diverse biological stimuli \[[@B23-ijms-18-00956],[@B24-ijms-18-00956],[@B25-ijms-18-00956]\]. In contrast to apoptosis which is programed cell death, necrosis is passive and activated by mechanical damage or disease \[[@B25-ijms-18-00956]\]. Interestingly, apoptotic bodies are released into the extracellular environment through several stages. During the early and intermediate stages, the cell membrane is contracted, the cytoplasm is condensed, and the cells become smaller in size \[[@B23-ijms-18-00956]\]. Simultaneously, nuclear chromatin is also condensed and undergoes alteration, and the plasma membrane deteriorates such that its permeability increases in the late stage. As a result, the plasma membrane undergoes a process that is commonly known as blebbing \[[@B24-ijms-18-00956]\]; and the cellular content is disintegrated into distinct membrane enclosed vesicles known as apoptotic bodies \[[@B24-ijms-18-00956]\]. Therefore, apoptotic bodies contain the cytoplasm, but does not necessarily include tightly packed organelles or nuclear fragments. However, if organelles are encapsulated within apoptotic bodies, these organelles have been shown to have their integrity maintained \[[@B23-ijms-18-00956]\]. During the formation process of apoptotic bodies, phosphatidylserine (PS) residues that are normally located on the internal surface of the plasma membrane, subsequently translocate to the external surface. This process presents extracellular signals that attract macrophages to clear the apoptotic bodies via phagocytosis ([Figure 2](#ijms-18-00956-f002){ref-type="fig"}).

2.2. Microvesicles {#sec2dot2-ijms-18-00956}
------------------

Microvesicles, also known as "ectosomes", are the second largest vesicle type between 100 and 1000 nm in diameter, which are formed by the outward budding and fission of the plasma membrane \[[@B26-ijms-18-00956],[@B27-ijms-18-00956]\]. However, there is limited understanding about the formation and shedding mechanism of microvesicles at the cell surface, although it is hypothesised that the formation of membrane microvesicles may be a result of the dynamic interplay between phospholipid redistribution and cytoskeletal protein contraction \[[@B28-ijms-18-00956],[@B29-ijms-18-00956]\]. This process is regulated by several enzymes such as calpain, flippase, floppase, scramblase and gelsolin \[[@B30-ijms-18-00956]\]. Flippases transfer phospholipids from the outer leaflet to the inner leaflet while floppases transfer phospholipids from the inner leaflet to the outer leaflet \[[@B31-ijms-18-00956]\]. The translocation of PS to the outer-membrane leaflet is a signal that induces the membrane budding/vesicle formation ([Figure 3](#ijms-18-00956-f003){ref-type="fig"}) \[[@B28-ijms-18-00956]\]. In addition, microvesicle formation was associated with ADP-ribosylation factor 6 (ARF6), a small GTPase protein, which regulating the activation of myosin light chain kinase (MLCK) and subsequent phosphorylation of MLCK lead to a promotion of contraction of actin-based cytoskeleton \[[@B32-ijms-18-00956]\]. Thereby, the budding process is completed through the contraction of cytoskeletal structures via actin and myosin interactions \[[@B32-ijms-18-00956],[@B33-ijms-18-00956]\].

2.3. Exosomes {#sec2dot3-ijms-18-00956}
-------------

Exosomes are the smallest class of EVs with diameters between 40 and 100 nm and a cup shape morphology according to previous studies using electron microscopy \[[@B34-ijms-18-00956]\]. Although the mechanism of exosome biogenesis is not fully understood, it is commonly accepted that exosomes are formed and developed via the endocytic pathway, and are subsequently released to the extracellular environment by exocytosis \[[@B35-ijms-18-00956],[@B36-ijms-18-00956]\]. The formation and release process begins when fluids, solutes, macromolecules, plasma components and particles are internalized by various endocytic trafficking pathways into transport vesicles \[[@B37-ijms-18-00956],[@B38-ijms-18-00956]\]. The transport vesicles then fuse with one another or with an existing sorting endosome to form early endosomes. During the next developmental stage, early endosomes may collect proteins and other components and develop into late endosomes, and that late endosome may recycle its components back to the plasma membrane or be subjected to degradation by lysosomes \[[@B37-ijms-18-00956],[@B39-ijms-18-00956]\]. Alternatively, that late endosomes may develop to become multi-vesicular bodies (MVBs) carrying and releasing exosomes when MVBs fuse with the cellular membrane ([Figure 4](#ijms-18-00956-f004){ref-type="fig"}) \[[@B39-ijms-18-00956],[@B40-ijms-18-00956]\]. Thus while complex and much remains unknown about exosome biogenesis, it is clear that their formation and release are tightly regulated by multiple signalling mechanisms. For instance, some evidence suggests that Endosomal Sorting Complexes Required for Transport (ESCRT) pathway is needed for exosome biogenesis \[[@B39-ijms-18-00956],[@B41-ijms-18-00956]\] as is Rab27a/b which is involved in endosome development and docking of MVBs to the cellular plasma membrane \[[@B42-ijms-18-00956]\].

3. Cell-to-Cell Communication {#sec3-ijms-18-00956}
=============================

Cell-to-cell communication is a pivotal mechanism that enables the differentiation of cells and the development of multicellular organisms. The mechanisms of cell-to-cell communication are very complex and involve intercellular and intracellular signals, which includes cell junctions, adhesion contacts and soluble factors \[[@B44-ijms-18-00956],[@B45-ijms-18-00956]\]. Cells can form bridges (cytonemes) to connect and exchange surface-associated cargo to neighbouring cells based on the mechanism of adhesion \[[@B46-ijms-18-00956]\], or tunnelling nanotubes to contact and transfer both cell surface molecules and cytoplasmic components to other cells \[[@B46-ijms-18-00956],[@B47-ijms-18-00956]\]. Recently, EVs were found to be a new means of communication because they carry functional molecules and can horizontally transfer these to neighbouring cells \[[@B19-ijms-18-00956]\].

Cell-to-cell communication by EVs is described as a way for cells to interact with neighbouring cells or one another over long distances, when EVs were detected in the circulation and other body fluids \[[@B44-ijms-18-00956]\]. The binding of EVs to target cells is specific with examples including: platelet-derived EVs binding to neutrophils \[[@B48-ijms-18-00956]\]; neutrophil-derived EVs binding to dendritic cells \[[@B49-ijms-18-00956]\] or to monocytes and endothelial cells \[[@B50-ijms-18-00956]\]; and leukocyte-derived EVs binding to platelets \[[@B51-ijms-18-00956]\]. The interaction between EVs and target cells are thought to require the coordinated action of the cytoskeleton and vesicle fusion machinery \[[@B28-ijms-18-00956]\]. Despite the limited understanding about EVs transport, different mechanisms of interaction between EVs and recipient cells include ligand--receptor interaction, internalisation and direct membrane fusion have been studied \[[@B52-ijms-18-00956]\] ([Figure 5](#ijms-18-00956-f005){ref-type="fig"}).

Examples of ligand--receptor interaction mechanisms include studies of EVs released from dendritic cells and platelets \[[@B53-ijms-18-00956],[@B54-ijms-18-00956]\]. Dendritic cell-derived exosomes contain MHC class II and CD9 on their membrane and were found to bind to the surface of activated T cells \[[@B53-ijms-18-00956]\]. This binding could be an interaction between MHC II molecules on exosome membranes and T cell receptors on T cell membranes \[[@B53-ijms-18-00956]\]. Interestingly, exosomes only bound to the surface of the plasma membrane without fusing and internalisation into T cells \[[@B53-ijms-18-00956]\]. Similarly, platelet-derived microvesicles containing the CD41 antigen were discovered to bind to the membrane of human bone marrow CD34^+^ cells, which then stimulated the adhesion of these cells to the endothelium as well as directed them from peripheral blood back into the bone marrow \[[@B54-ijms-18-00956]\].

Regarding the mechanism of direct membrane fusion, some evidences suggested that microvesicles fused directly with the plasma membrane and transferred their contents to the intracellular milieu of the recipient cells \[[@B55-ijms-18-00956],[@B56-ijms-18-00956],[@B57-ijms-18-00956],[@B58-ijms-18-00956]\]. In the case of microvesicles enriched selectively with P-selectin glycoprotein ligand-1 (PSGL-1), the fusion may be controlled by Annexin V or antibody to PSGL-1 \[[@B55-ijms-18-00956]\]. Additionally, it seems that the fusion of EVs to the plasma membrane is also dependant on SNARE proteins, which regulate the fusion and target specificity in intracellular vesicle trafficking \[[@B58-ijms-18-00956]\]. When EVs fuse with and transfer membrane components such as receptors and ligands to their targets, these can increase the resistance to apoptosis in the case of macrophages receiving chemokine receptors; or induce an increased frequency of apoptosis in the case of T lymphocytes receiving the Fas ligand (a death-receptor ligand) \[[@B56-ijms-18-00956],[@B57-ijms-18-00956]\].

Morelli et al. found evidence of the internalisation of circulating EVs into dendritic cells, phagocytes of spleen, and Kupffer cells in the liver via clathrin-dependent endocytosis \[[@B59-ijms-18-00956]\]. This internalisation of EVs by dendritic cells requires participation of the dendritic cell cytoskeleton as well as surface molecules such as externalised PS, CD11a, CD54, CD9 and CD81 \[[@B59-ijms-18-00956]\]. Additionally, cellular maturity also influences the internalisation of EVs by dendritic cells, since immature dendritic cells exhibit a higher internalisation capability than mature dendritic cells \[[@B59-ijms-18-00956]\]. This internalisation of EVs into target cells could induce peripheral T-cell tolerance in the absence of danger signals \[[@B59-ijms-18-00956]\] or stimulate cell proliferation and migration \[[@B21-ijms-18-00956]\].

4. Functional Components of EVs {#sec4-ijms-18-00956}
===============================

4.1. Proteins {#sec4dot1-ijms-18-00956}
-------------

In general, all three populations of mammalian EVs share some common characteristics such as structure (lipid bi-layer), and tend to have common types of cargo such as protein, lipid or genetic material. However, these characteristics may be distinct depending on the manner of formation as well as the nature of their parental cells. Specific molecules that are unique to each vesicle population can be used to distinguish between them. For example, PS is only transferred to the external plasma membrane surface when cells undergo apoptosis and where microvesicles are formed and shed \[[@B28-ijms-18-00956],[@B60-ijms-18-00956]\]. In another example, the tetraspanin family (e.g., CD9, CD63, and CD81) form a complex network of interacting molecules which play a role in trafficking of transmembrane proteins \[[@B61-ijms-18-00956]\]. Thus CD9, CD63, and CD81 are enriched and often detected in exosomes since they are often involved in exosome biogenesis pathways \[[@B8-ijms-18-00956],[@B52-ijms-18-00956],[@B62-ijms-18-00956]\], however these components are also detected in other vesicles \[[@B63-ijms-18-00956]\]. Interestingly, CD24 could be considered as a marker of exosomes isolated from urine and amniotic fluids \[[@B8-ijms-18-00956]\]. Additionally, the CD24 has been found to be over-expressed in various cancer cell lines such as ovarian, breast, non-small cell lung, prostate and pancreatic carcinomas \[[@B64-ijms-18-00956]\]. In terms of other functional proteins, Dujarin et al. reported that Tau, a microtubule-associated protein, and matrix metalloproteinase 1 (MMP-1) protein, were enriched in microvesicles compared to exosomes \[[@B17-ijms-18-00956],[@B65-ijms-18-00956]\]. However, no studies have reported whether or not Tau and MMP-1 proteins are enriched in apoptotic bodies.

Importantly, specific EV biomolecular cargo has previously been linked to cancer and tumour development \[[@B50-ijms-18-00956],[@B66-ijms-18-00956],[@B67-ijms-18-00956]\]. For example, apoptotic bodies, which contained DNA encoding the oncogenes H-rasV12 and c-myc, were found to induce tumour formation and growth in severe combined immunodeficient (SCID) mice \[[@B66-ijms-18-00956]\]. Interestingly, the authors also found that these H-rasV12 and c-myc genes were replicated and incorporated into the recipient genome in newly formed tumour cells in vivo (SCID mice model) \[[@B66-ijms-18-00956]\]. Furthermore, microvesicles carrying MMP-9 released from breast carcinoma cells, fibrosarcoma cells and polymorphonuclear leucocytes functioned in the digestion of the extracellular matrix, which is necessary for the progress of cancer growth and inflammation \[[@B50-ijms-18-00956],[@B67-ijms-18-00956]\].

EVs have also been found to carry components associated with angiogenesis and coagulation processes \[[@B55-ijms-18-00956],[@B68-ijms-18-00956],[@B69-ijms-18-00956]\]. For instance, endothelial cell-derived microvesicles, which were enriched with MMPs, could stimulate the invasion and formation of capillary-like structures of human umbilical vein endothelial cells (HUVECs) \[[@B69-ijms-18-00956]\]. Indeed, MMPs have been identified as important mediators of angiogenesis \[[@B70-ijms-18-00956],[@B71-ijms-18-00956]\], but exactly how the EV MMPs contribute to the angiogenic process has not yet been revealed. Interestingly, the accumulation of MMPs within microvesicles was shown to be stimulated by angiogenic factors including, fibroblast growth factor (FGF)-2 and vascular endothelial growth factor (VEGF) \[[@B69-ijms-18-00956]\]. Moreover, EVs were also associated with coagulation since microvesicles contained tissue factor (TF) derived from platelets and monocytes \[[@B55-ijms-18-00956],[@B68-ijms-18-00956]\].

EVs also have a function in the regulation of immune responses, since exosomes have been found to contain major histocompatibility complex (MHC) class I and II molecules and may transfer these molecules to dendritic cells \[[@B5-ijms-18-00956],[@B72-ijms-18-00956],[@B73-ijms-18-00956]\]. The transferral of MHC I molecules from melanoma cell line-derived exosomes to dendritic cells, triggered the production of Interferon γ in these cells \[[@B73-ijms-18-00956]\]. Furthermore, MHC I molecules carried by dendritic cell derived exosomes could activate CD8+ T cell responses \[[@B5-ijms-18-00956],[@B73-ijms-18-00956]\]. These studies indicate that exosomes can potentially act as extracellular antigen sources, which could help to develop immune interventions.

Finally, cytoplasmic proteins, such as tubulin, actin, actin-binding proteins, annexins and Rab proteins, which are involved in intracellular membrane fusion and transport, and ESCRT machinery complex proteins are also found in exosomes \[[@B39-ijms-18-00956],[@B41-ijms-18-00956],[@B74-ijms-18-00956],[@B75-ijms-18-00956]\]. In addition, molecules responsible for signal transduction, such as protein kinases, 14-3-3 and heterotrimeric G proteins, are enveloped during exosome formation and release \[[@B39-ijms-18-00956],[@B74-ijms-18-00956],[@B76-ijms-18-00956],[@B77-ijms-18-00956]\]. While there is evidence to support the conclusion that the molecular components of EVs may be delivered to and elicit functional responses in recipient cells, unequivocal evidence is still required \[[@B19-ijms-18-00956]\]. Taken together, these studies indicate that EVs and their cargo are functional and could influence recipient cell behaviour.

4.2. Lipids {#sec4dot2-ijms-18-00956}
-----------

Interestingly, EV lipid composition, which includes cholesterol, sphingomyelin, ceramide, phospholipids and glucans can provide an additional means of identification for exosomes \[[@B78-ijms-18-00956],[@B79-ijms-18-00956],[@B80-ijms-18-00956],[@B81-ijms-18-00956]\]. Indeed, exosomes have been found to be enriched with higher amounts of cholesterol and sphingolipids, including sphingomyelin and hexosylceramide, but contain lower amounts of accumulated phosphatidylcholine, compared to parent cell membranes \[[@B81-ijms-18-00956]\]. Importantly, Trajkovic et al. showed that high concentrations of ceramide exist in the micro-domains where multi-vesicular endosomes are formed. This led to the hypothesis that ceramide could be useful for enlarging micro-domains and facilitating the inducement of domain budding \[[@B81-ijms-18-00956]\]. These studies indicate that lipids can partially regulate the formation and release of vesicles \[[@B78-ijms-18-00956],[@B81-ijms-18-00956]\].

4.3. Genetic Materials (Messenger RNAs and miRNAs) {#sec4dot3-ijms-18-00956}
--------------------------------------------------

Regarding genetic biomolecules, RNAs including messenger RNAs (mRNAs) and microRNAs (miRNAs) have also been found in EVs which have been increasingly found to elicit various functions in recipient cells \[[@B11-ijms-18-00956],[@B82-ijms-18-00956],[@B83-ijms-18-00956],[@B84-ijms-18-00956],[@B85-ijms-18-00956],[@B86-ijms-18-00956],[@B87-ijms-18-00956],[@B88-ijms-18-00956],[@B89-ijms-18-00956],[@B90-ijms-18-00956]\]. In particular, large amounts of mRNAs and miRNAs were found in all three EV types released from both cell cultures and body fluids \[[@B14-ijms-18-00956],[@B82-ijms-18-00956],[@B83-ijms-18-00956],[@B84-ijms-18-00956],[@B87-ijms-18-00956],[@B88-ijms-18-00956],[@B89-ijms-18-00956],[@B90-ijms-18-00956]\]. Importantly, these EV-derived genetic molecules were selectively sorted into EVs and as such could be used for diagnostics, such as cancer markers, or as potential treatment targets \[[@B90-ijms-18-00956],[@B91-ijms-18-00956],[@B92-ijms-18-00956],[@B93-ijms-18-00956],[@B94-ijms-18-00956]\]. In addition to carrying the information from secreting cells, EV mRNAs and miRNAs can also function to promote biological processes, including proliferation, angiogenesis and apoptosis \[[@B86-ijms-18-00956],[@B92-ijms-18-00956],[@B95-ijms-18-00956],[@B96-ijms-18-00956]\]. Interestingly, there is evidence showing that EV mRNAs were horizontally transferred to recipient cells and are able to be translated into proteins \[[@B3-ijms-18-00956],[@B95-ijms-18-00956],[@B96-ijms-18-00956]\]. Additionally, the proteins translated from transferred EV mRNAs have been shown to activate PI3K/AKT signalling pathways in recipient endothelial cells \[[@B96-ijms-18-00956]\] and accelerate morphological and functional recovery in rat liver \[[@B95-ijms-18-00956]\]. While these studies provide some evidence for the role of EV mRNAs and miRNAs in the regulation of biological processes, it is clear that further studies are required to more fully understand the functional consequences of EV genetic cargo.

5. The Role of EVs in Cutaneous Wound Healing {#sec5-ijms-18-00956}
=============================================

Wound healing is an essential process that enables the restoration of the structure and function of damaged or injured tissues. For most tissues, the process requires multiple cell types from several distinct lineages where each responds to and generates a range of signals at different times \[[@B97-ijms-18-00956]\]. The wound healing process involves a series of overlapping phases including: haemostasis; inflammation; migration; and tissue remodelling \[[@B16-ijms-18-00956]\]. During these phases, a series of precise biological events occur including: rapid vascular spasms, platelet plug formation and coagulation (collectively known as haemostasis); inflammation; cell migration into the wound site; cell proliferation and differentiation to form granulation tissue; angiogenesis; and extracellular-matrix reorganisation \[[@B97-ijms-18-00956]\]. Evidence for the involvement of EVs in wound healing has been described for coagulation, cell proliferation, cell migration and angiogenesis and summarised in [Table 1](#ijms-18-00956-t001){ref-type="table"} \[[@B17-ijms-18-00956],[@B18-ijms-18-00956],[@B19-ijms-18-00956],[@B21-ijms-18-00956]\].

5.1. Coagulation {#sec5dot1-ijms-18-00956}
----------------

The blood coagulation cascade is complex and regulated by a range of factors such as calcium ions, PS and TF in addition to many others. TF is an initiator of coagulation activation that was found to be present on the plasma membrane of EVs, including microvesicles and exosomes, which were derived from various cell types such as human monocytes/macrophages \[[@B55-ijms-18-00956]\] human platelets \[[@B98-ijms-18-00956]\]; and EVs isolated from human saliva \[[@B99-ijms-18-00956]\]. Indeed, monocyte-derived microvesicles enriched with TF and PSDL-1 were found to bind, fuse and transfer their content to collagen-activated platelets \[[@B55-ijms-18-00956]\]. The result of this TF transfer from microvesicles to the platelets enabled TF to become "decrypted"/activated, and thus initiate the extrinsic coagulation cascade leading to conversion of prothrombin to thrombin and fibrin clot formation \[[@B55-ijms-18-00956]\]. Furthermore, in an in vitro study, salivary EVs that contain TF in association with coagulation factor VII significantly reduced the clotting time of human wound blood ([Figure 6](#ijms-18-00956-f006){ref-type="fig"}) \[[@B99-ijms-18-00956]\]. Similarly, EVs carrying TF from pericardial blood of cardiac surgery patients induced coagulation in vitro and stimulated thrombogenicity in rats \[[@B98-ijms-18-00956]\]. Conversely, EVs from the venous blood of healthy individuals also carrying TF did not reduce clotting time \[[@B98-ijms-18-00956]\]. This may be due to soluble inhibitors including Tissue Factor Pathway Inhibitor (TFPI) or conformational regulation of TF in plasma that impedes the binding of coagulation factor VII and inhibits its activity \[[@B55-ijms-18-00956]\].

5.2. Cell Proliferation {#sec5dot2-ijms-18-00956}
-----------------------

Cell proliferation, a pivotal cellular process underpinning wound healing, has been shown to be regulated by EVs derived from a plethora of cell types, such as human mesenchymal stem cells (MSCs) \[[@B21-ijms-18-00956],[@B100-ijms-18-00956],[@B101-ijms-18-00956]\], fibroblasts \[[@B18-ijms-18-00956]\], murine embryonic stem cells \[[@B102-ijms-18-00956]\], and human endothelial progenitor cells \[[@B103-ijms-18-00956]\]. The regulation of cell proliferation by EVs occurred through the binding to or internalisation of EVs into recipient cells and delivery of EV content such as RNAs \[[@B104-ijms-18-00956],[@B105-ijms-18-00956]\]. For instance, the internalisation of EVs into fibroblasts greatly enhanced the cell proliferation due to the activation of the Akt and Erk1/2 effector pathway by EVs \[[@B18-ijms-18-00956],[@B21-ijms-18-00956],[@B100-ijms-18-00956],[@B106-ijms-18-00956],[@B107-ijms-18-00956]\]. Additionally, embryonic stem cell-derived EVs may facilitate fibroblast proliferation, possibly through the activation of the mitogen-activated protein kinase (MAPK) pathway \[[@B102-ijms-18-00956]\]. Importantly, these aforementioned activated pathways induce the expression of a number of genes involved in cell cycle progression such as c-myc, cyclin A1 and cyclin D2 which then support cell proliferation \[[@B21-ijms-18-00956],[@B106-ijms-18-00956]\]. Furthermore, activation of these pathways also promoted the production of growth factors, including insulin-like growth factor-1 (IGF-1), stromal-derived growth factor-1 (SDF-1) and cytokine interleukin-6 (IL-6), VEGF-α and transforming growth factor beta (TGF-β) \[[@B18-ijms-18-00956],[@B21-ijms-18-00956],[@B101-ijms-18-00956],[@B102-ijms-18-00956]\]. Thus, it seems clear that EVs can promote cell proliferation by activation of signalling pathways not only directly involved in stimulation of cell cycle but also involved in the regulation of growth factor expression. Additionally, this growth factor expression can act in a paracrine or autocrine fashion to further stimulate cell growth responses.

5.3. Migration {#sec5dot3-ijms-18-00956}
--------------

Following clotting, immune cells including neutrophils and macrophages are recruited to remove necrotic tissues, debris, and bacteria from the wound site. Within hours after injury, other cells including epithelial cells and fibroblasts migrate into the wound site to perform specific tasks, such as induction of growth factor secretion, the synthesis of extracellular matrix, angiogenesis and stimulation of wound closure \[[@B97-ijms-18-00956]\]. Preliminary studies have been conducted investigating the involvement of EVs in the migration of various cells associated with cutaneous repair, such as human and murine epithelial cells \[[@B108-ijms-18-00956]\], bovine endothelial cells \[[@B109-ijms-18-00956]\], human MSCs \[[@B100-ijms-18-00956]\], human keratinocytes and fibroblasts in vitro \[[@B110-ijms-18-00956]\].

Evidently, keratinocyte migration has been shown to be influenced by EVs released from various cell types; however, different results were observed depending on the specific biomolecules carried by the EVs \[[@B110-ijms-18-00956],[@B111-ijms-18-00956]\]. For example, CoCl~2~-treated tumour cell-derived exosomes which contained C4.4A (Ly6/PLAUR domain-containing protein 3), α6β4 integrin and MMP-14 inhibited keratinocyte migration through degradation of laminin 332 resulting in delayed wound closure \[[@B111-ijms-18-00956]\]. Conversely, keratinocyte derived exosomes with heat-shock protein (HSP) 90α cargo significantly enhanced the migration of primary human keratinocytes in a wound scratch model \[[@B110-ijms-18-00956]\]. Additionally, the migration of endothelial cells, which are crucial for vascular repair and regeneration, has also been shown to be influenced by EVs released from cells such as human keratinocytes \[[@B108-ijms-18-00956]\], human MSCs \[[@B112-ijms-18-00956],[@B113-ijms-18-00956]\]; and bovine endothelial cells \[[@B109-ijms-18-00956]\]. However, the mechanisms that facilitate EV mediated endothelial migration are unclear.

In a wound healing context, fibroblasts are known to release growth factors which induce other cells to proliferate and migrate, and also produce collagen (COL) that provides structure to the wound \[[@B16-ijms-18-00956],[@B114-ijms-18-00956]\]. Interestingly, EVs have been shown to regulate the migration of fibroblasts towards wound sites \[[@B104-ijms-18-00956],[@B105-ijms-18-00956],[@B110-ijms-18-00956]\]. Cheng et al. showed that TGFα stimulates HSP90α secretion from human keratinocytes via the exosome pathway \[[@B110-ijms-18-00956]\]. Most exosomes contain some member of the heat-shock protein (HSP) family, such as HSP70 and HSP90 \[[@B39-ijms-18-00956],[@B76-ijms-18-00956],[@B115-ijms-18-00956]\]. This protein family supports the folding of nascent peptides; prevents the aggregation of proteins; assists with the transportation of other proteins across cell membranes \[[@B116-ijms-18-00956]\], and can induce cell motility \[[@B115-ijms-18-00956],[@B117-ijms-18-00956]\]. Interestingly, human keratinocyte conditioned media containing exosomes with HSP90α cargo was found to stimulate the rapid migration of dermal fibroblasts \[[@B110-ijms-18-00956]\]. HSP90α is comprised of four domains, including an N-terminal domain, a charged sequence connected to the N-terminal domain, a middle domain and a C-terminal domain \[[@B118-ijms-18-00956]\]. It is thought that HSP90α may promote cell migration through binding interactions with the cell surface receptor LRP-1/CD91 \[[@B110-ijms-18-00956],[@B117-ijms-18-00956]\]. Furthermore, in corroboration with cell migration enhancement, EVs released from mesenchymal stem cells and keratinocytes were also shown to promote the expression of important genes such as TGF-β, transforming growth factor beta receptor II, COL I, COL III, N-cadherin, cyclin-1, MMP-1, MMP-3 and IL-6 in fibroblasts \[[@B104-ijms-18-00956],[@B105-ijms-18-00956]\]. These genes are involved in the Erk1/2 signalling pathway, which has roles in both cell proliferation and migration.

5.4. Angiogenesis {#sec5dot4-ijms-18-00956}
-----------------

New blood vessel formation is critical for wound healing in order to supply nutrients and oxygen to newly formed tissues. The formation of new blood vessels requires the proliferation of endothelial cells, as well as the interaction between endothelial cells, angiogenic factors (such as VEGF and fibroblast growth factor) and surrounding ECM proteins \[[@B119-ijms-18-00956]\]. Under chemotaxis, endothelial cells penetrate the underlying vascular basement membrane, invade ECM stroma and form tube-like structures that continue to extend, branch, and create networks \[[@B119-ijms-18-00956],[@B120-ijms-18-00956]\]. Interestingly, all three populations of EVs (apoptotic bodies, microvesicles and exosomes) contribute to the regulation of vessel formation by enhancing the expression of pro-angiogenic factors \[[@B21-ijms-18-00956],[@B92-ijms-18-00956],[@B102-ijms-18-00956],[@B103-ijms-18-00956],[@B106-ijms-18-00956],[@B107-ijms-18-00956],[@B109-ijms-18-00956],[@B112-ijms-18-00956],[@B120-ijms-18-00956],[@B121-ijms-18-00956]\]. For example, exosomes released from human embryonic MSCs \[[@B92-ijms-18-00956],[@B113-ijms-18-00956]\] and human endothelial cells \[[@B103-ijms-18-00956],[@B106-ijms-18-00956]\] enhanced angiogenesis by promoting endothelial cell proliferation and migration towards the wound site. Furthermore, a large number of blood vessels were observed in exosome-treated sites compared to control treatment \[[@B106-ijms-18-00956],[@B107-ijms-18-00956],[@B112-ijms-18-00956]\].

Interestingly, various critical pro-angiogenic genes, including IL-6, IL-8, angiopoietin-1, E-selectin, and fibroblast growth factor 2, which activate the Erk1/2 signalling pathway, were up-regulated after platelet-rich plasma and endothelial progenitor cell-derived exosome stimulation \[[@B106-ijms-18-00956],[@B122-ijms-18-00956]\]. Additionally, the downstream target of the Erk1/2 signalling pathway such as inhibitor of DNA binding 1, cyclooxygenase 1, VEGFA, VEGFR-2, c-Myc and cyclin-D1, were also increased after treatment with exosomes \[[@B106-ijms-18-00956],[@B122-ijms-18-00956],[@B123-ijms-18-00956]\]. This provides further evidence that exosomes enhance endothelial cell function through activation of the Erk1/2 signalling pathway ([Figure 7](#ijms-18-00956-f007){ref-type="fig"}) \[[@B106-ijms-18-00956]\]. In contrast, microvesicles from multiple cellular sources inhibited tube-like structure formation of microvascular endothelial cells via CD36 on the treated cell membrane, while exosome derived from the same cell source as the microvesicles did not have the same inhibitory activity \[[@B124-ijms-18-00956]\]. Taken together, the previous studies imply that EVs could potentially be used in vascular regenerative medicine. Moreover, the EV bioactivities may depend on EV types and the physiological conditions of administered cells However, further research is required to investigate which specific EV derived biomolecules are responsible for the stimulation of angiogenesis.

5.5. Collagen Production and ECM Remodelling {#sec5dot5-ijms-18-00956}
--------------------------------------------

Successful wound healing requires the contribution of many cellular events and biological processes in addition to coagulation, cell proliferation, cell migration and angiogenesis. Besides the involvement of EVs in the above events, EVs have also been shown to regulate ECM remodelling which is the last phase of wound healing. For example, EVs have been shown to stimulate an increase in elastin secretion, which is a structural protein of the ECM \[[@B102-ijms-18-00956],[@B112-ijms-18-00956]\]. Furthermore, when wound sites are treated with MSC-derived exosomes, an increase of COL I and III were observed in the early stage of wound healing \[[@B105-ijms-18-00956],[@B112-ijms-18-00956],[@B125-ijms-18-00956]\]. However, in the late stage of wound healing, exosomes may inhibit collagen expression \[[@B105-ijms-18-00956]\]. Interestingly, EVs catalyse the crosslinking of collagen in the ECM via lysyl oxidase-like 2 (LOXL2), which is located on the exterior of the exosome membrane \[[@B126-ijms-18-00956]\]. In addition, a study by Huleihel et al. (2016) observed that EVs present within the ECM were closely associated with the collagen network of the matrix, but these EVs could be separated from the fibre network \[[@B127-ijms-18-00956]\]. This may indicate that EVs attend to the ECM formation and function. Furthermore, EVs have also been demonstrated to significantly increase the healing rate and reduce scar widths by interaction with Annexin A1 and formyl peptide receptors in a rat model \[[@B107-ijms-18-00956],[@B108-ijms-18-00956],[@B125-ijms-18-00956]\]. Taken together, these studies indicate that EVs play a pivotal role in the ECM remodelling phase of wound healing.

6. Conclusions {#sec6-ijms-18-00956}
==============

In the past, EVs were disregarded simply as cellular debris. However, current research has demonstrated that EVs contain bioactive molecules and are able to deliver these to recipient cells via newly described cell-to-cell communication mechanisms. In wound healing, EVs were initially shown to regulate inflammation, proliferation, migration, angiogenesis, collagen production and ECM remodelling. Such regulation could be mediated through the enhancement of gene expression, suppression of gene translation, and/or activation of signalling pathways important for wound healing processes. However, the current level of knowledge regarding how the EV molecular cargo regulates the process of wound healing remains unclear. Therefore, more research is required to clarify the regulation of EVs during the wound healing process, and to translate these results to the clinic.
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![Wound healing process. The normal tissue repair process is comprised of continuous and overlapping phases. These four phases include: (i) Haemostasis; (ii) inflammation; (iii) proliferation; and (iv) remodelling. Each phase consists of different cellular events which requires the interplay of multiple cell populations \[[@B22-ijms-18-00956]\].](ijms-18-00956-g001){#ijms-18-00956-f001}

![Formation of apoptotic bodies and clearance by phagocytosis. Formation of apoptotic bodies includes the condensation and segregation of the nucleus, and the deterioration and blebbing of the plasma membrane. The result of these processes is a separation of the cellular contents into membrane-enclosed vesicles which can be cleared by phagocytic cells.](ijms-18-00956-g002){#ijms-18-00956-f002}

![Phospholipid translocase activity via floppase and flippase which translocates phosphatidylserine and other phospholipids from the inner leaflet to the outer leaflet, and outer leaflet to inner leaflet, respectively, during microvesicle formation. These processes are adenosine triphosphate (ATP)-dependant \[[@B28-ijms-18-00956],[@B30-ijms-18-00956],[@B32-ijms-18-00956],[@B33-ijms-18-00956]\].](ijms-18-00956-g003){#ijms-18-00956-f003}

![Exosome biogenesis. Beginning from internalization of membrane proteins and lipid complexes by endocytosis, endocytotic vesicles are delivered to early endosomes, which fuse with each other resulting in formation of late endosomes/multivesicular bodies (MVB). MVBs either release exosomes by fusion with the cellular membrane, or their contents are degraded if they fuse with lysosomes \[[@B40-ijms-18-00956],[@B42-ijms-18-00956],[@B43-ijms-18-00956]\]. The key steps of the exosomal formation and development process are highlighted in red.](ijms-18-00956-g004){#ijms-18-00956-f004}

![Interaction of EVs with target cells: (**A**) intracellular signalling due to EV membrane ligand cell surface receptor interactions \[[@B53-ijms-18-00956],[@B54-ijms-18-00956]\]; (**B**) direct membrane fusion which induces cell function through release of EV cargo into target cells \[[@B55-ijms-18-00956],[@B56-ijms-18-00956],[@B57-ijms-18-00956],[@B58-ijms-18-00956]\]; and (**C**) internalisation of EVs into target cells, prior to the release of their cargo into the recipient cell cytoplasm inducing functional effects \[[@B21-ijms-18-00956],[@B59-ijms-18-00956]\].](ijms-18-00956-g005){#ijms-18-00956-f005}

![Promotion of coagulation by TF-barring microvesicle treatment. Rapid coagulation is triggered by the initiating TF/Factor VII and promotion of fibrin strand formation \[[@B98-ijms-18-00956],[@B99-ijms-18-00956]\].](ijms-18-00956-g006){#ijms-18-00956-f006}

![Promotion of angiogenesis by MSC-derived exosomes. Exosomes released from human MSCs can induce expression of genes and activate PI3K/Akt and Erk1/2 signalling pathways in endothelial cells leading to promotion tube formation and newly formed vessels.](ijms-18-00956-g007){#ijms-18-00956-f007}
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###### 

Summary of research investigating EVs involvement in wound healing.

  Events                                    EV Types                                      Parental Cells             Target Cells          Secreted Factors/Factors Presented in EVs                                                                                                                        Molecules/Pathways Activated                                                                                                                                                                                                                              References
  ----------------------------------------- --------------------------------------------- -------------------------- --------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------
  Coagulation                               Mv, Ex                                        Saliva/granulocytes, EPC   Blood                 TF                                                                                                                                                               Trigger coagulation by initiating TF/factor VII                                                                                                                                                                                                           \[[@B99-ijms-18-00956]\]
  Mv                                        Monocytes                                     Activated Platelet         TF, PSGL-1                                                                                                                                                                             \[[@B55-ijms-18-00956]\]                                                                                                                                                                                                                                  
  Mv                                        Plasma/Platelet, erythrocytes, granulocytes   Blood                      TF                    Promote thrombus formation                                                                                                                                       \[[@B98-ijms-18-00956]\]                                                                                                                                                                                                                                  
  Proliferation                             Ex                                            MSC                        FB, EC                                                                                                                                                                                 Increase expression levels of HGF, IGF1, NGF, SDF1; increase re-epithelialisation; reduce scar widths; promote collagen maturity and the creation of newly formed vessels; accelerate maturation of wound sites; activate Akt, Erk and Stat3 signalling   \[[@B21-ijms-18-00956],[@B112-ijms-18-00956]\]
  Ex/nanoparticles \*                       ESC                                           FB                                               Enhance the expression levels of mRNA, EVGFα, TGFβ, collagen I, Ki-67                                                                                            \[[@B102-ijms-18-00956]\]                                                                                                                                                                                                                                 
  Mv, Ex                                    MyoFB                                         FB, EC                                                                                                                                                                                                            \[[@B18-ijms-18-00956]\]                                                                                                                                                                                                                                  
  Ex                                        KC                                            FB                         HSP90                 Could not promote cell proliferation                                                                                                                             \[[@B110-ijms-18-00956]\]                                                                                                                                                                                                                                 
  Ex                                        Platelet-rich plasma                          EC                         VEGF, bFGF, PDGFBB    Activating Pi3K/Akt and Erk signalling pathway                                                                                                                   \[[@B107-ijms-18-00956]\]                                                                                                                                                                                                                                 
  Ex                                        EC, EPC                                       EC                                               Activating Erk1/2 signalling pathway                                                                                                                             \[[@B103-ijms-18-00956],[@B106-ijms-18-00956]\]                                                                                                                                                                                                           
  Mv                                        Platelet-rich plasma after exercise           HUVEC                                                                                                                                                                                                             \[[@B128-ijms-18-00956]\]                                                                                                                                                                                                                                 
  Migration                                 Ex                                            MSC                        FB, EC                                                                                                                                                                                 Induction the expression of HGF, IGF1, NGF, SDF1; activate Akt, Erk and Stat3 signalling                                                                                                                                                                  \[[@B21-ijms-18-00956],[@B112-ijms-18-00956]\]
  Ex                                        KC                                            KC, HDMECs                 HSP90                 Hsp90-Ex increased cell migration without the need to bind any cofactor or ATP; CD91 is receptor of extracellular Hsp90; TGFβ could not inhibit cell migration   \[[@B110-ijms-18-00956]\]                                                                                                                                                                                                                                 
  Ex/Ev                                     EC                                            Murine wound               Annexin-I                                                                                                                                                                              \[[@B108-ijms-18-00956]\]                                                                                                                                                                                                                                 
  Ex/nanop-articles \*                      ESC                                           FB                                               Higher expression of mRNA, EVGFα, TGFβ, collagen I, Ki-67                                                                                                        \[[@B102-ijms-18-00956]\]                                                                                                                                                                                                                                 
  Ex                                        Platelet-rich plasma                          EC                         VEGF, bFGF, PDGFBB    Activating Pi3K/Akt and Erk signalling pathway                                                                                                                   \[[@B107-ijms-18-00956]\]                                                                                                                                                                                                                                 
  Ex                                        EC, EPC                                       EC                                               Activating Erk1/2 signalling pathway                                                                                                                             \[[@B103-ijms-18-00956],[@B106-ijms-18-00956]\]                                                                                                                                                                                                           
  Ex                                        hUSC                                          HUVEC                                                                                                                                                                                                             \[[@B121-ijms-18-00956]\]                                                                                                                                                                                                                                 
  Ev                                        Multiple cellular sources                     EC                         CD63                                                                                                                                                                                   \[[@B124-ijms-18-00956]\]                                                                                                                                                                                                                                 
  Angiogenesis                              Ex                                            MSC                        FB, EC                                                                                                                                                                                 Induction the expression of HGF, IGF1, NGF, SDF1; promote the creation and maturation of newly formed vessels, increase re-epithelialisation, reduce scar widths                                                                                          \[[@B21-ijms-18-00956],[@B112-ijms-18-00956]\]
  Ex/nanop-articles\*                       ESC                                           FB                                               Enhance the expression levels of mRNA, EVGFα, TGFβ, collagen I, Ki-67                                                                                            \[[@B102-ijms-18-00956]\]                                                                                                                                                                                                                                 
  Mv, Ex                                    MyoFB                                         Fb, EC                     VEGF, FGF2            Increase angiogenesis                                                                                                                                            \[[@B18-ijms-18-00956]\]                                                                                                                                                                                                                                  
  Ex                                        Platelet-rich plasma                          EC                         VEGF, bFGF, PDGFBB    Activating Pi3K/Akt and Erk signalling pathway                                                                                                                   \[[@B107-ijms-18-00956]\]                                                                                                                                                                                                                                 
  Ex                                        EC                                            EC                                               Activating Erk1/2 signalling pathway                                                                                                                             \[[@B103-ijms-18-00956],[@B106-ijms-18-00956]\]                                                                                                                                                                                                           
  Ex                                        MSC                                           EC                         EMMPRIN, VEGF, MMP9   ERK/Akt pathway                                                                                                                                                  \[[@B123-ijms-18-00956]\]                                                                                                                                                                                                                                 
  Ex                                        MSC                                           EC                         miR-125a              Direct target DLL4                                                                                                                                               \[[@B92-ijms-18-00956]\]                                                                                                                                                                                                                                  
  Ex                                        hUSC                                          HUVEC                                                                                                                                                                                                             \[[@B121-ijms-18-00956]\]                                                                                                                                                                                                                                 
  Ex                                        Epithelium cells                              EC                         VEGFR                                                                                                                                                                                  \[[@B129-ijms-18-00956]\]                                                                                                                                                                                                                                 
  Ev                                        Multiple cellular sources                     EC                         CD63                                                                                                                                                                                   \[[@B124-ijms-18-00956]\]                                                                                                                                                                                                                                 
  Mv                                        Platelet-rich plasma after exercise           HUVEC                                                                                                                                                                                                             \[[@B128-ijms-18-00956]\]                                                                                                                                                                                                                                 
  Collagen production and ECM remodelling   Ex                                            MSC                        FB                    TF                                                                                                                                                               Increase reepithelialisation, reduce scar widths, promote collagen maturity and maturation of wound sites                                                                                                                                                 \[[@B112-ijms-18-00956]\]
  Ex                                        MSCs, FB                                      FB                                               Increase collagen production                                                                                                                                     \[[@B105-ijms-18-00956],[@B125-ijms-18-00956]\]                                                                                                                                                                                                           
  Ex                                        Hypoxic EC                                    ECM                        LOXL2                 ECM remodelling                                                                                                                                                  \[[@B126-ijms-18-00956]\]                                                                                                                                                                                                                                 

FB: Fibroblasts, KC: Keratinocytes, MSCs: Mesenchymal stem cells, EC: Endothelial cells, ESC: Embryonic stem cells, EPC: Epithelial cells, hUSC: Human urine derived stem cells, HUVUEC: Human umbilical vein endothelial cells, Mv: Microvesicle(s), Ex: Exosome(s), EMMPRIN: Extracellular matrix metalloproteinase inducer, (\*) nanoparticles mimicking. Exosome were extracted from living cells.
